Evergraf 0.25mg tablets | Everolimus | MHP

EVERGRAF 0.25MG

DESCRIPTION:

Evergraf 0.25mg is a derivative of Rapamycin (sirolimus) and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor.
It is normally used as an immunosuppressant to prevent rejection of organ transplants.
In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.

PRESCRIBING INFORMATION:

Evergraf 0.25mg tablet are mainly indicated for the treatment of Renal carcinoma.
Evergraf 0.25mg  are mainly indicated for the treatment of Breast carcinoma.
Evergraf 0.25mg tablet are mainly indicated for the treatment of Brain carcinoma.
Evergraf 0.25mg is also used in various advanced stage cancer in stomach, intestines or pancreas.

MECHANISM OF ACTION:

Everolimus is an mTOR prohibitor, joints at high compatibility to FK506 binding protein 12, via producing drug complex which inhibits the specific of mTOR.
This inhibition decreases the activity of effectors downstream, that may cause blockage of cell progression from G1 into S phase, subsequently causes cell growth arrest and apoptosis.

Evergraf 0.25mg

PRODUCT  DETAIL:

Brand : Evergraf
Ingredients : Everolimus
Strength : 0.25mg
Manufactured : Panacea Biotech Ltd
Package : 10 tablets

PHARMACOKINETICS

ABSORPTION:

The high plasma concentration time of Everolimus is 1 to 2 hours.The effect of food with Evergraf 0.25mg that with heavy meal: Reduction of systemic exposure to Evergraf 0.25mg, and the high blood plasma concentration by 54%.

DISTRIBUTION:

Evergraf 0.25mg human plasma protein bound with the range of 74%.

METABOLISM:

The metabolism of Everolimus is occurred in liver, which is a substrate of CYP3A4.
The metabolites of Everolimus;
Three monohydroxylated metabolite
Two hydrolytic rings opened products
Phosphatidylcholine conjugate of Everolimus.

EXCRETION:

The major route of elimination;
5% in urine; the parent compound has been detected in urine or feces.
The half-life period of Everolimus is relatively 30 hours

DOSAGE MANAGEMENT:

In breast cancer, renal cell cancer, pancreatic cancer, Neuro endocrine cancer:
The prescribed dosage is 10mg should be taken as a single dose.
In Brain or intracranial cancer:
The prescribed dosage of Evergraf 0.25mg is 4.5mg/m2 orally as a single dose.
In pediatric:
The usual pediatric dosage of Evergraf 0.25mg in brain or intracranial tumor is 4.5mg/m2 should be taken orally as a single dose.
Evergraf 0.25mg tablet should be administered with or without food.

PRECAUTIONS:

Lymphomas:

Increased exposure of skin cancers, patient may protect from UV light

Serious infections:

Patients receiving Evergraf 0.25mg have high risk of acquiring various infections related to bacteria, virus, and fungi. Anti-microbial agents are preferred for the suspected patients.

Hepatic artery thrombosis:

In liver transplant patients, Evergraf 0.25mg therapy should not be recommended.

Nephrotoxicity:

Renal function should be monitored frequently; caution should be taken while using Evergraf 0.25mg in renal impaired patients.

Angioedema:

This may have occurred in the patients receiving concomitantly Evergraf 0.25mg with Angiotensin converting enzyme agents
Hyperlipidemia:
Patient getting Evergraf 0.25mg with lipid lowering drugs causes increasing in plasma concentration of these drugs causes hyperlipidemia
Interstitial lung disease: Occurred in Evergraf 0.25mg therapy
Interact with grape juice:
Causes increasing blood levels of Everolimus; avoid these concomitants.

SIDE EFFECTS:

• Hypersensitivity reactions
• Lymphomas & other malignancy
• Serious infections
• Kidney graft thrombosis
• Hepatic artery thrombosis
• Nephrotoxicity
• Hyperlipemia
• Angioedema
• Interstitial lung disease
• Thrombocytopenia
• Male infertility
• Proteinuria
• New commencement of diabetes .

DRUG INTERACTION:

• Evergraf 0.25mg interaction with strong inhibitor of CYP3A4, or P-gp, leads to cause decreasing the efflux of Everolimus and increase the plasma concentration of Everolimus.
• Combination of Evergraf 0.25mg with verapamil leads to increasing the plasma concentration of Everolimus.
• Combination of Evergraf 0.25mg with Atorvastatin or pravastatin causes rhabdomyolysis, due to increasing concentration of lipid lowering agents.
• Evergraf 0.25mg combination with strong CYP3A4 inducers, causes increasing the exposure of Everolimus
. • Concomitant use of Evergraf 0.25mg with cyclosporine causes increasing the AUC level of Everolimus frequently.
• Evergraf 0.25mg tablet is interaction with ketoconazole or other CYP3A4 inhibitors causes increasing the plasma concentration and AUC of Everolimus.
• Concomitant use with erythromycin causes increasing in AUC of Everolimus.

CONTRAINDICATIONS:

Some anaphylactic reaction occurs, if patients are contraindicated to the components present in the Evergraf 0.25mg tablet

PREGNANCY:

Pregnancy category C Evergraf 0.25mg is needed only by the patients after knowing the benefits to the mother outweighs the risk to fetus.

LACTATION:

Breast feeding should not be suggested

STORAGE :

Evergraf 0.25mg tablet should be kept at 25°C
Keep the tablet away from moisture, heat and light
Dispense only in original container.

MISSED DOSE:

If patient failed to take a single dose, patients must consult with medical practitioner and follow the instructions given by them. Or the missed dose should be avoiding and follow the regular dosing schedule.

OVERDOSAGE:

The over dosage of Everolimus is rarely occur, in case of over dosage patient must be provide with supportive measures. The acute toxicity of Everolimus over dosage should be monitored.
 

CONTACT US:

PHONE NO:+91-9940472902

E-MAIL: millionhealthpharmaceuticals@gmail.com

WEBSITE URL: https://millionpharma.com/evergraf-0.25-mg.php